CompletedNot Applicable

rTMS and Botulinum Toxin in Benign Essential Blepharospasm

United States12 participantsStarted 2015-02

Plain-language summary

Benign essential blepharospasm (BEB) is a functionally disabling focal dystonia. Botulinum neurotoxin (BoNT) therapy is suboptimal in many BEB patients. Repetitious transcranial magnetic stimulation (rTMS) therapy is a promising noninvasive therapy and has shown positive benefits in BEB. rTMS therapy can be easily combined with BoNT injections to enhance the effects of BoNT in BEB.

Who can participate

Age range30 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * subjects diagnosed with blepharospasm or cranio-cervical dystonia who receive BoNT therapy at the Center for Movement Disorders will be approached. The investigators will enroll only those subjects who report experiencing positive benefits with BoNT but lasting about 10 weeks or less. Exclusion Criteria: * pregnancy * active seizure disorder * significant cognitive impairment * exposure to neuroleptics * presence of a metallic body such as pacemaker, implants, prosthesis, artificial limb or joint, shunt, metal rods and hearing aid.

What they're measuring

Change in JRS Severity Score

Timeframe: 2 weeks after rTMS

Change in JRS Frequency Score

Timeframe: 2 weeks after rTMS

Change in Number of Sustained Forced Eye Blinks

Timeframe: 2 weeks after rTMS

Change in Duration of Forced Blinks

Timeframe: 2 weeks after rTMS

Trial details

NCT IDNCT02370875

SponsorUniversity of Florida

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2017-05

Results submitted2022-05-23

View on ClinicalTrials.gov More Benign Essential Blepharospasm trials